Neuvivo is a late clinical-stage biopharmaceutical company developing a new ALS treatment.
Neuvivo has raised $11.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2023.
Neuvivo's investors include Primestreet Group.
Neuvivo is headquartered in Palo Alto, United States.
Neuvivo is a late clinical-stage biopharmaceutical company developing a new ALS treatment.
Neuvivo is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Neuvivo — Funding & Investors." VCBacked, June 15, 2023, https://www.vcbacked.co/company/neuvivo. Accessed August 15, 2026.
VCBacked. (2023). Neuvivo — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/neuvivo
{{cite web |title=Neuvivo — Funding & Investors |url=https://www.vcbacked.co/company/neuvivo |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated